Targeting inflammation using salsalate in patientswith type 2 diabetes: Effects on flow-mediated dilation (TINSAL-FMD)

Diabetes Care

Volumn 36, Issue 12, 2013, Pages 4132-4139

  Goldfine, Allison B ^a,b   Stewart Buck, J ^b,h   Desouza, Cyrus ^c,d   Fonseca, Vivian ^e   Chen, Yii Der Ida ^f,i   Shoelson, Steven E ^a   Jablonski, Kathleen A ^g   Creager, Mark A ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^e TULANE UNIVERSITY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h EMORY UNIVERSITY HOSPITAL   (United States)

ⁱ Los Angeles Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SALSALATE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BRACHIAL ARTERY; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; FEMALE; FLOW MEDIATED DILATION; GLUCOSE TOLERANCE TEST; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; BLOOD; BLOOD FLOW; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ECHOGRAPHY; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; SALICYLATES; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84891843085     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0859     Document Type: Article

References (43)

1. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444-2452
2. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874
4. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSALT2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010;152: 346-357
5. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008;1:36-43
6. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31: 289-294
7. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2013;50:537-543
8. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27
9. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-234
10. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF Jr, Creager MA. Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2003;285:H2392-H2398
11. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flowmediated dilation in the community: the Framingham Heart Study. Circulation 2004;109:613-619
12. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26: 1235-1241
13. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for longterm cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-1775
14. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multiethnic study of atherosclerosis. Circulation 2009;120:502-509
15. Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013;159:1-12
16. Corretti MC, Anderson TJ, Benjamin EJ, et al.; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265
17. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996;78:1210-1214
18. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70
19. Donato AJ, Eskurza I, Silver AE, et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium- dependent dilation and upregulation of nuclear factorkappaB. Circ Res 2007;100:1659-1666
20. Tabit CE, Shenouda SM, Holbrook M, et al. Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus. Circulation 2013;127:86-95
21. Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factorkappaB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009;119: 1284-1292
22. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-2363
23. Koh KK, Han SH, Chung WJ, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004;93:1432-1435, A10
24. Sugiura T, Kondo T, Kureishi-Bando Y, et al. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 2008;52:491-498
25. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013;56:714-723
26. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-255
27. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31:451-
28. Kullo IJ, Hensrud DD, Allison TG. Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30,> or =30). Am J Cardiol 2002;89:1441-1443
29. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455-461
30. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353: 1649-1652
31. Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 2005;15:266-271
32. Grimm RH Jr, Neaton JD, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and allcause mortality. JAMA 1985;254:1932-1937
33. Rana JS, Boekholdt SM, Ridker PM, et al. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med 2007;262:678-689
34. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293: 1673-1677
35. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-959
36. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelialleukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996;156:3961-3969
37. Westerheide SD, Morimoto RI. Heat shock responsemodulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005;280:33097-33100
38. Aceves M, Dueñas A, Gómez C, San Vicente E, Crespo MS, García-Rodríguez C. A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription. J Immunol 2004;173:5721-5729
39. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 2003;278:24944-24950
40. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein-and NF-kappa B-responsive genes. J Immunol 1999;163: 5608-5616
41. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogenactivated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997;94:2869-2873
42. Nixon M, Wake DJ, Livingstone DE, et al. Salicylate downregulates 11beta-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes 2012;61: 790-796
43. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-922